Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

This was the stock's fourth consecutive day of losses.

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Regeneron has shown that adding its investigational LAG-3 inhibitor fianlimab to its PD-1 inhibitor Libtayo (cemiplimab) delivers impressive results in advanced melanoma. Long-term data from a Phase I ...